|
Renovorx, Inc. (RNXT) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
RenovoRx, Inc. (RNXT) Bundle
Bewerten Sie den finanziellen Ausblick von Renovorx, Inc. (RNXT) wie ein Experte! Dieser (RNXT) DCF-Taschenrechner bietet vorgefüllte Finanzdaten sowie die Flexibilität, das Umsatzwachstum, WACC, Margen und andere wesentliche Annahmen zu ändern, um sich an Ihren Projektionen auszurichten.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | .0 | .0 | -5.7 | -9.9 | -11.4 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | 3.9 | 3.2 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -3.9 | -3.2 | -5.7 | -10.0 | -11.4 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 2.1 | 1.8 | 15.2 | 6.4 | 1.2 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | .5 | .2 | .5 | .5 | .6 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -3.8 | -3.7 | -6.4 | -9.8 | -11.4 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | .6 | -.9 | -6.0 | -9.8 | -11.4 | -.6 | .0 | .0 | .0 | .0 |
| WACC, % | 9.19 | 9.19 | 9.19 | 9.19 | 9.19 | 9.19 | 9.19 | 9.19 | 9.19 | 9.19 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -1 | |||||||||
| Net Debt | -1 | |||||||||
| Equity Value | 1 | |||||||||
| Diluted Shares Outstanding, MM | 10 | |||||||||
| Equity Value Per Share | 0.06 |
What You Will Get
- Comprehensive RNXT Financials: Access historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Real-Time Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Explore various scenarios to assess RenovoRx's future performance.
- User-Friendly Design: Designed for industry professionals while remaining approachable for newcomers.
Key Features
- Customizable Treatment Parameters: Adjust essential inputs like treatment efficacy, patient demographics, and operational costs.
- Instant Efficacy Analysis: Provides real-time assessments of treatment outcomes and cost-effectiveness.
- High-Precision Results: Utilizes RenovoRx’s proprietary data for accurate treatment valuations.
- Streamlined Scenario Testing: Easily evaluate various treatment scenarios and analyze their impacts.
- Efficiency Booster: Avoid the hassle of developing intricate treatment models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered RenovoRx, Inc. (RNXT) data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for RenovoRx, Inc. (RNXT)’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose RenovoRx, Inc. (RNXT) Calculator?
- Comprehensive Tool: Offers DCF, WACC, and financial ratio analyses all in one platform.
- Customizable Inputs: Modify the highlighted cells to explore different financial scenarios.
- Detailed Insights: Automatically computes RenovoRx’s intrinsic value and Net Present Value.
- Preloaded Data: Access to historical and projected data for reliable analysis.
- Professional Quality: Perfect for financial analysts, investors, and business consultants in the healthcare sector.
Who Should Use This Product?
- Investors: Accurately assess RenovoRx’s fair value before making investment decisions.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to RenovoRx (RNXT).
- Consultants: Efficiently customize the template for valuation reports tailored to RenovoRx (RNXT) clients.
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms.
- Educators: Implement it as a teaching resource to illustrate valuation methodologies relevant to the biotech sector.
What the Template Contains
- Preloaded RNXT Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.